FDA
-
-
-
-
-
-
-
Mallinckrodt Announces Publication of Findings on Treatment Patterns and Outcomes in Patients with Two Types of Arthritis Treated with Acthar® Gel (repository corticotropin injection)
-
-
-
-
-
-
-
Mallinckrodt Presents Data on TERLIVAZ® (terlipressin) for Injection in Patients with Hepatorenal Syndrome-Acute Kidney Injury (HRS-AKI) at the American College of Gastroenterology (ACG) Annual Meeti
-
-
-
-
-
-
-
Mallinckrodt plc Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides 2024 Guidance
-
-
-
-
-
-
-
Mallinckrodt Presents Latest Health Economics Data on Acthar® Gel (Repository Corticotropin Injection) at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023
-
-
-
-
-
-
-
Mallinckrodt Presents Clinical Data for TERLIVAZ® (terlipressin) for Injection in Adults with Hepatorenal Syndrome (HRS) at Digestive Disease Week (DDW) 2023
-
-
-
-
-
-
-
Mallinckrodt Presents New TERLIVAZ® (terlipressin) for Injection Data on Hepatorenal Syndrome (HRS) Reversal at the Society of Critical Care Medicine (SCCM) 2023 Critical Care Congress
-
-
-
-
-
-
-
Mallinckrodt Announces U.S. FDA Approval of StrataGraft® (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen - dsat)
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

